Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc. The launch is scheduled to take place in September 2025.
According to IQVIA sales data, the Halaven Injection market achieved annual sales of approximately $66.3 million for the 12-month period ending July 2025. The company’s President and Business Head, North America, Marc Kikuchi, expressed his pleasure at the launch, stating that it marks the company’s commitment to growing its portfolio of products within the institutional channel and reinforces its dedication to providing quality and affordable alternatives to patients in need.
Glenmark’s Eribulin Mesylate Injection is only approved for the indications listed in the company’s approved label. The product will be distributed in the US market, and the company is confident that it will make a significant impact in the pharmaceutical industry.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a presence in branded, generics, and OTC segments. The company has a focus on therapeutic areas such as respiratory, dermatology, and oncology. It has 11 world-class manufacturing facilities spread across four continents and operations in over 80 countries.
The company has been ranked among the top 100 biopharmaceutical companies by Pharmaceutical Sales in 2023 and among the top 50 generics and biosimilar companies by sales in 2024. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved by the Science Based Target initiative (SBTi), making it the second pharmaceutical company in India to achieve this.
The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. With the launch of Eribulin Mesylate Injection, Glenmark Pharmaceuticals Inc., USA, aims to continue its mission of providing quality and affordable pharmaceutical products to patients in need.
The launch of this product is a significant milestone for the company, and it is expected to have a positive impact on the pharmaceutical industry. Glenmark’s commitment to providing quality and affordable alternatives to patients in need is evident in its dedication to growing its portfolio of products within the institutional channel.
As the company continues to expand its presence in the US market, it is likely to face competition from other pharmaceutical companies. However, with its strong portfolio of products and commitment to quality and affordability, Glenmark Pharmaceuticals Inc., USA, is well-positioned to make a significant impact in the industry.
In conclusion, the launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials, by Glenmark Pharmaceuticals Inc., USA, is a significant development in the pharmaceutical industry. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, and is expected to provide a quality and affordable alternative to patients in need.